The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 27381369)

Published in Diabetes on July 05, 2016

Authors

Simon A Hawley1, Rebecca J Ford2, Brennan K Smith2, Graeme J Gowans1, Sarah J Mancini3, Ryan D Pitt2, Emily A Day2, Ian P Salt3, Gregory R Steinberg4, D Grahame Hardie5

Author Affiliations

1: Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland, U.K.
2: Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
3: Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, U.K.
4: Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada d.g.hardie@dundee.ac.uk gsteinberg@mcmaster.ca.
5: Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland, U.K. d.g.hardie@dundee.ac.uk gsteinberg@mcmaster.ca.